ACKNOWLEDGEMENTS
The authors thank the participating patients and their caregivers, and
the study centers and investigators for their contributions to the
study. This study was funded by Wuhan Clinical Medical Research Project
(WX20D20, WZ20Y04, WX21Z48)References
1. Rosenthal J. Hematopoietic cell transplantation-associated thrombotic
microangiopathy: a review of pathophysiology, diagnosis, and treatment.J Blood Med . 2016;7:181-6. doi:10.2147/jbm.S102235
2. Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble
in the kidneys and beyond: hematopoietic stem cell
transplantation-associated thrombotic microangiopathy. Blood . Aug
11 2011;118(6):1452-62. doi:10.1182/blood-2011-02-321315
3. [Chinese consensus on the diagnosis and management of
transplant-associated thrombotic microangiopathy (2021)].Zhonghua Xue Ye Xue Za Zhi . Mar 14 2021;42(3):177-184.
doi:10.3760/cma.j.issn.0253-2727.2021.03.001
4. Matsui R, Hagino T, Tsuno NH, et al. Does time of CCI measurement
affect the evaluation of platelet transfusion effectiveness?Transfus Apher Sci . Jun 2021;60(3):103123.
doi:10.1016/j.transci.2021.103123
5. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant
clinical trials network toxicity committee consensus summary: thrombotic
microangiopathy after hematopoietic stem cell transplantation.Biol Blood Marrow Transplant . Aug 2005;11(8):571-5.
doi:10.1016/j.bbmt.2005.06.001
6. Epperla N, Li A, Logan B, et al. Incidence, Risk Factors for and
Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J
Haematol . Jun 2020;189(6):1171-1181. doi:10.1111/bjh.16457
7. Heybeli C, Sridharan M, Alkhateeb HB, et al. Characteristics of late
transplant-associated thrombotic microangiopathy in patients who
underwent allogeneic hematopoietic stem cell transplantation. Am J
Hematol . Jul 2 2020;doi:10.1002/ajh.25922
8. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for
hematopoietic stem cell transplant-associated microangiopathy: results
of a consensus process by an International Working Group.Haematologica . Jan 2007;92(1):95-100. doi:10.3324/haematol.10699
9. Cho BS, Yahng SA, Lee SE, et al. Validation of recently proposed
consensus criteria for thrombotic microangiopathy after allogeneic
hematopoietic stem-cell transplantation. Transplantation . Oct 27
2010;90(8):918-26. doi:10.1097/TP.0b013e3181f24e8d
10. Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for
HSCT-associated thrombotic microangiopathy: a study in children and
young adults. Blood . Jul 24 2014;124(4):645-53.
doi:10.1182/blood-2014-03-564997
11. Wirtschafter E, VanBeek C, Linhares Y. Bone marrow
transplant-associated thrombotic microangiopathy without peripheral
blood schistocytes: a case report and review of the literature.Exp Hematol Oncol . 2018;7:14. doi:10.1186/s40164-018-0106-9
12. Dvorak CC, Higham C, Shimano KA. Transplant-Associated Thrombotic
Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A
Practical Approach to Diagnosis and Management. Front Pediatr .
2019;7:133. doi:10.3389/fped.2019.00133
13. Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic
microangiopathy: theoretical considerations and a practical approach to
an unrefined diagnosis. Bone Marrow Transplant . Aug
2021;56(8):1805-1817. doi:10.1038/s41409-021-01283-0
14. Seaby EG, Gilbert RD. Thrombotic microangiopathy following
haematopoietic stem cell transplant. Pediatr Nephrol . Sep
2018;33(9):1489-1500. doi:10.1007/s00467-017-3803-4
15. Mulay S, Kreuter JD, Bryant SC, et al. Outcomes of plasma exchange
in patients with transplant-associated thrombotic microangiopathy based
on time of presentation since transplant. J Clin Apher . Jun
2015;30(3):147-53. doi:10.1002/jca.21352
16. Jodele S, Laskin BL, Goebel J, et al. Does early initiation of
therapeutic plasma exchange improve outcome in pediatric stem cell
transplant-associated thrombotic microangiopathy? Transfusion .
Mar 2013;53(3):661-7. doi:10.1111/j.1537-2995.2012.03776.x
17. Yang LP, Zhao P, Wu YJ, et al. Treatment outcome and efficacy of
therapeutic plasma exchange for transplant-associated thrombotic
microangiopathy in a large real-world cohort study. Bone Marrow
Transplant . Apr 2022;57(4):554-561. doi:10.1038/s41409-022-01581-1
18. McFadyen JD, Stevens H, Peter K. The Emerging Threat of
(Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.Circ Res . Jul 31 2020;127(4):571-587.
doi:10.1161/circresaha.120.317447
19. Kim SS, Patel M, Yum K, Keyzner A. Hematopoietic stem cell
transplant-associated thrombotic microangiopathy: review of
pharmacologic treatment options. Transfusion . Feb
2015;55(2):452-8. doi:10.1111/trf.12859
20. Higham CS, Shimano KA, Melton A, et al. A pilot trial of
prophylactic defibrotide to prevent serious thrombotic microangiopathy
in high-risk pediatric patients. Pediatr Blood Cancer . May
2022;69(5):e29641. doi:10.1002/pbc.29641
21. Jodele S, Dandoy C, Lane A, et al. Complement blockade for TA-TMA:
lessons learned from a large pediatric cohort treated with eculizumab.Blood . 2020;135(13):1049-1057. doi:10.1182/blood.2019004218
Table 1 Clinical and demographic characteristics of pediatric patients
with TA-TMA